These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28982547)

  • 1. HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life.
    Bae S; Sim T; Lim C; Kim D; Lee J; Park Y; Jung S; Choi I; Kwon S; Oh KT
    Int J Pharm; 2017 Dec; 534(1-2):89-96. PubMed ID: 28982547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
    J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.
    Flores MV; Hickling TP; Sreckovic S; Fidock MD; Horscroft N; Katragadda M; Savic B; Rawal J; Delpuech-Adams OE; Robas N; Corey T; Nelms L; Lawton M; Marcek J; Stubbs M; Westby M; Ciaramella G
    Antivir Ther; 2012; 17(5):869-81. PubMed ID: 22505586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
    Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
    Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.
    Bruno R; Sacchi P; Scagnolari C; Torriani F; Maiocchi L; Patruno S; Bellomi F; Filice G; Antonelli G
    Aliment Pharmacol Ther; 2007 Aug; 26(3):369-76. PubMed ID: 17635371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.
    Kneteman NM; Weiner AJ; O'Connell J; Collett M; Gao T; Aukerman L; Kovelsky R; Ni ZJ; Zhu Q; Hashash A; Kline J; Hsi B; Schiller D; Douglas D; Tyrrell DL; Mercer DF
    Hepatology; 2006 Jun; 43(6):1346-53. PubMed ID: 16729319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.
    Lupberger J; Duong FH; Fofana I; Zona L; Xiao F; Thumann C; Durand SC; Pessaux P; Zeisel MB; Heim MH; Baumert TF
    Hepatology; 2013 Oct; 58(4):1225-35. PubMed ID: 23519785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.
    Liu WL; Yang HC; Hsu CS; Wang CC; Wang TS; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14799-14804. PubMed ID: 27930338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection.
    Kneteman NM; Asthana S; Lewis J; Dibben C; Douglas D; Nourbakhsh M; Tyrrell LJ; Lund G
    Liver Transpl; 2012 Jan; 18(1):38-44. PubMed ID: 21837737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
    Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
    Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.